Capsule inhaler ICOcap™ from Iconovo CE-marked for clinical trials
Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials. ICOcap™ is now available for customers…
Development of Iconovo AB’s generic Symbicort project transferred to the global partner Amneal
Iconovo AB today announced that the ICOres™ budesonide/formoterol project (generic Symbicort®) will be transferred to the global partner Amneal Ireland Limited from CBC Corporation (India) Private Limited. Amneal Ireland Limited will take over all existing obligations of CBC under the current agreement. The project will continue according to plan.
ICONOVO AB CARRIES OUT A DIRECTED SHARE ISSUE AND RAISES SEK 60 MILLION BEFORE ISSUE COSTS
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND,…
Iconovo has been granted ICOres patent in Japan
The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several granted ICOres patents in Sweden…
ICONOVO AND CRYSTECPHARMA TO COLLABORATE IN DEVELOPMENT OF INNOVATIVE INHALER PRODUCTS
Iconovo today announced that it signed a Letter of Understanding with CrystecPharma to collaborate in the development of innovative dry powder inhaler…
ICONOVO AB (PUBL) MAKES A SIGNIFICANT INVESTMENT IN THE DEVELOPMENT OF A NEW INHALATION PLATFORM
Iconovo AB (publ) announced today that the company has made a decision to invest in the development of a new dry powder inhalation platform. This platform…
